Panitumumab

Drug Profile

Panitumumab

Alternative Names: ABX-EGF; Anti-EGFR monoclonal antibody - Abgenix; E7.6.3; Panitumab; rHuMAb-EGFr; Vectibix

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Takeda; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase II Bladder cancer; Breast cancer; Neuroendocrine tumours
  • Phase I Solid tumours
  • Discontinued Head and neck cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 02 Mar 2017 National Institute for Health and Care Excellence (NICE) recommends panitumumab for metastatic colorectal cancer for previously untreated patients
  • 01 Mar 2017 Amgen completes the phase III ASPECCT trial in Colorectal cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in USA, Australia, Belgium, Bulgaria, Canada, China, Czech Republic, France, Hong Kong, India, Israel, Italy, Latvia, Lithuania, Malaysia, Netherlands, Peru, Philippines, Poland, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, South Korea, Sweden, Taiwan, and UK (NCT01001377)
  • 01 Dec 2016 Amgen initiates enrolment in the phase II UCGI28_PANIRINOX trial for Colorectal cancer (Combination therapy, Metastatic disease) in France (NCT02980510)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top